Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06835504 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Morphine or Ketamine for Analgesia

Study acronym: MoKA
StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: May 1, 2026 to Sep 1, 2026 Primary completion pushed from Apr 30, 2029 to Aug 30, 2029 · Completion pushed from Oct 31, 2029 to Feb 28, 2030v4 Show 2 more changesShow less
    • Primary completion pushed from Apr 30, 2029 to Aug 30, 2029
    • Completion pushed from Oct 31, 2029 to Feb 28, 2030
  2. Start date: Feb 17, 2026 to May 1, 2026 Primary completion date: Jan 31, 2029 to Apr 30, 2029 · Completion date: Jul 31, 2029 to Oct 31, 2029v3 Show 2 more changesShow less
    • Primary completion date: Jan 31, 2029 to Apr 30, 2029
    • Completion date: Jul 31, 2029 to Oct 31, 2029
  3. Start date: Sep 1, 2025 to Feb 17, 2026 Primary completion date: Aug 31, 2028 to Jan 31, 2029 · Completion date: Feb 28, 2029 to Jul 31, 2029v2 Show 2 more changesShow less
    • Primary completion date: Aug 31, 2028 to Jan 31, 2029
    • Completion date: Feb 28, 2029 to Jul 31, 2029
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pain is common in children presenting to the emergency department but is frequently undertreated, leading to both short- and long-term consequences. Morphine is the standard treatment for children with moderate to severe acute pain, but its use is associated with serious side effects and caregiver and clinician concerns related to opioid administration. The investigators aim to determine if sub-dissociative ketamine is non-inferior to morphine for treating acute pain and a preferable alternative for treating acute pain in children because of its more favorable side effect profile and potential long-term benefits related to pain-related function, analgesic use/misuse, and mental and behavioral health outcomes.
Trial Details
NCT Number NCT06835504
Lead Sponsor Columbia University
Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Neurological Disorders and Stroke (NINDS)
Conditions Abdominal Pain, Isolated Extremity Fracture, Pain, Pediatrics
Enrollment 1,010 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov